PharmAust Ltd
PharmAust Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials… Read more
PharmAust Ltd (PAA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: -0.501x
Based on the latest financial reports, PharmAust Ltd (PAA) has a cash flow conversion efficiency ratio of -0.501x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-5.12 Million) by net assets (AU$10.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PharmAust Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how PharmAust Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
PharmAust Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PharmAust Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Arctic Fish Holding AS
OL:AFISH
|
-0.068x |
|
Capital & Regional Plc
PINK:CRPLF
|
0.039x |
|
Fortune Rise Acquisition Corp
NASDAQ:FRLA
|
-0.009x |
|
Singular Genomics Systems Inc
NASDAQ:OMIC
|
-0.161x |
|
Optomed PLC
HE:OPTOMED
|
-0.052x |
|
The Cato Corporation
F:CO2A
|
-0.074x |
|
Korea New Network Co. Ltd
KQ:058400
|
0.023x |
|
TRJNF
PINK:TRJNF
|
N/A |
Annual Cash Flow Conversion Efficiency for PharmAust Ltd (2013–2024)
The table below shows the annual cash flow conversion efficiency of PharmAust Ltd from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-06-30 | AU$10.23 Million | AU$-5.17 Million | -0.505x | -25.64% |
| 2023-06-30 | AU$3.89 Million | AU$-1.56 Million | -0.402x | -136.81% |
| 2022-06-30 | AU$7.84 Million | AU$-1.33 Million | -0.170x | -60.80% |
| 2021-06-30 | AU$8.88 Million | AU$-937.97K | -0.106x | +29.09% |
| 2020-06-30 | AU$8.53 Million | AU$-1.27 Million | -0.149x | +28.54% |
| 2019-06-30 | AU$7.46 Million | AU$-1.55 Million | -0.208x | +4.06% |
| 2018-06-30 | AU$7.14 Million | AU$-1.55 Million | -0.217x | -19.64% |
| 2017-06-30 | AU$6.92 Million | AU$-1.26 Million | -0.182x | +42.99% |
| 2016-06-30 | AU$5.02 Million | AU$-1.60 Million | -0.318x | -60.75% |
| 2015-06-30 | AU$8.84 Million | AU$-1.75 Million | -0.198x | +2.66% |
| 2014-06-30 | AU$7.80 Million | AU$-1.59 Million | -0.204x | +79.29% |
| 2013-06-30 | AU$310.88K | AU$-305.46K | -0.983x | -- |